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Abstract
The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly 
reactive antibodies, several of which neutralize over 90% of HIV-1 strains. To understand how 
antibodies achieve such neutralization, we isolated CD4-binding-site (CD4bs) antibodies and 
analyzed 16 co-crystal structures –8 determined here– of CD4bs antibodies from 14 donors. The 
16 antibodies segregated by recognition mode and developmental ontogeny into two types: CDR 
H3-dominated and VH-gene-restricted. Both could achieve greater than 80% neutralization 
breadth, and both could develop in the same donor. Although paratope chemistries differed, all 16 
gp120-CD4bs antibody complexes showed geometric similarity, with antibody-neutralization 
breadth correlating with antibody-angle of approach relative to the most effective antibody of each 
type. The repertoire for effective recognition of the CD4 supersite thus comprises antibodies with 
distinct paratopes arrayed about two optimal geometric orientations, one achieved by CDR H3 
ontogenies and the other achieved by VH-gene-restricted ontogenies.
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Successful vaccines often recapitulate effective immune responses induced by natural 
infection. In the case of HIV-1, antibodies capable of neutralizing about half of circulating 
strains develop after years of chronic infection in about half of examined donors (Hraber et 
al., 2014). Isolation and mapping of these neutralizing responses show that they target most 
of the exposed surface of the prefusion mature closed state of the HIV-1 Env spike (Julien et 
al., 2013; Lyumkis et al., 2013; Pancera et al., 2014). Despite this broad targeting, highly 
effective antibodies develop preferentially against just a few sites of vulnerability on HIV-1 
Env. These “supersites” of vulnerability have been the focus of intense vaccine interest. 
Each supersite appears to be targeted by broadly neutralizing antibodies that arise in many 
infected individuals, by broadly neutralizing antibodies with diverse modes of recognition, 
and by broadly neutralizing antibodies with diverse B cell ontogenies (reviewed in (Kwong 
and Mascola, 2012; West et al., 2014)). Thus the human immune system has multiple 
avenues by which to generate effective antibodies against these supersites, thereby providing 
a rationale for their suitability as focuses of vaccine efforts.
One of these supersites, the CD4 supersite, is the site of binding for the CD4 receptor on the 
HIV-1 gp120 envelope glycoprotein. All primate immunodeficiency viruses recognize CD4 
as the primary attachment molecule on the cell surface (Hoxie et al., 1988; McClure et al., 
1987) and therefore, despite the great genomic and hence antigenic variation between HIV-1 
strains, the CD4bs is relatively well conserved (Kwong et al., 1998; Lyumkis et al., 2013; 
Pancera et al., 2014). Potent broadly neutralizing CD4-binding-site (CD4bs) antibodies are 
frequently observed during the chronic stage of infection (Binley et al., 2008; Li et al., 2007; 
Lynch et al., 2012; Pancera et al., 2014; Walker et al., 2010), and numerous CD4bs 
antibodies have been identified (Burton et al., 1994; Corti et al., 2010; Georgiev et al., 2013; 
Liao et al., 2013; Scheid et al., 2011; Wu et al., 2010; Wu et al., 2011; Zhu et al., 2013). 
Analysis of co-crystal structures of core gp120s with three of these CD4bs antibodies, b12, 
VRC01, and CH103, reveal distinct modes of structural interaction (Liao et al., 2013; Zhou 
et al., 2010; Zhou et al., 2007), all of which involve substantial interactions with the 
conformationally invariant gp120-outer domain.
Additional antibody co-crystal structures (Zhou et al., 2013), however, showed CD4bs 
antibodies from different donors could have similar modes of recognition and similar B cell 
ontogenies – suggesting that the repertoire of effective CD4bs antibodies might be limited. 
Because an understanding of the variation in binding characteristics of antibodies specific 
for a supersite is expected to provide insight regarding how such antibodies might be 
induced in the general population, we sought to study antibody recognition of the CD4 
supersite in multiple donors. We used antigen-specific probes to isolate CD4bs antibodies 
from diverse germline VH genes. We determined co-crystal structures with the HIV-1-Env 
gp120 glycoprotein for these and for previously identified antibodies HJ16, 1B2530, 
8ANC131 and 8ANC134 (Corti et al., 2010; Scheid et al., 2011), and characterized B cell 
ontogenies and paratope chemistries. The repeated observation of similar CD4bs antibodies 
in 14 donors provided a means to delineate the repertoire for effective recognition of the 
CD4 supersite. The results define structural geometries, recognized surfaces, paratope 
chemistries, and developmental pathways of CD4bs recognition, thereby providing a 
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population-level understanding of antibodies targeting the CD4 supersite as well as a 
catalogue from which to choose optimal templates for vaccine re-elicitation.
RESULTS
Identification of CD4bs antibodies with diverse germline origin genes
To provide a more comprehensive view for how human antibodies recognize the CD4 
supersite, we sought to identify CD4bs antibodies from additional donors. In particular we 
were interested in determining whether highly effective neutralizing antibodies could 
originate from heavy chain germline genes other than VH1-2 or VH1-46, the germline 
origin genes from which virtually all previously identified effective CD4bs antibodies 
derive. Sera from donors 44, C38, and Z258 showed a substantial reduction in neutralization 
when adsorbed with the RSC3 probe, a modified core gp120 designed to retain only the 
outer domain contact of CD4 (Wu et al., 2010). With donor 44, we used RSC3 sorting (Wu 
et al., 2010) and PCR recovery of individual B cell antibody variable regions (Scheid et al., 
2009; Tiller et al., 2008) to isolate an antibody named “44-VRC13.01” (named for “donor-
antibody lineage.clone”; after the first mention of the complete antibody name, we refer to 
each antibody by its lineage name) (Figure S1). VRC13 utilized a VH gene derived from 
VH1-69 (Figure S1) and neutralized 82% of circulating HIV-1 isolates (Table S1). From 
donor C38, we isolated two antibodies: C38-VRC16.01 and C38-VRC18.02 (Figure S1). 
VRC16 utilized a VH gene derived from VH3-23 and neutralized 58% of HIV-1 strains; 
VRC18 utilized a VH gene derived from VH1-2, was highly similar to an NGS-derived 
antibody from donor C38 (Zhu et al., 2013), and neutralized 67% of HIV-1 strains (Table 
S1). From donor Z258, we isolated antibody Z258-VRC27.01. This antibody utilized a VH 
gene derived from VH1-2 and neutralized 78% of HIV-1 (Figure S1, Table S1). Altogether, 
we identified four potent and broadly neutralizing CD4bs antibodies, two of which were 
derived from VH genes not previously observed in effective CD4bs antibodies.
Two types of CD4bs antibody recognition
To define the structural modes of antibody recognition, we produced antigen-binding 
fragments and crystallized these in complex with extended core versions of the HIV-1 gp120 
envelope glycoprotein (Kwon et al., 2012). In addition to the four newly identified 
antibodies, we determined structures for antibodies from three donors with broadly 
neutralizing antibodies that had not been characterized structurally: the VH3-30-derived 
antibody HJ16 from donor 242315 (Corti et al., 2010; North et al., 2011) as well as the 
VH1-46-derived antibodies 1B2530 from donor RU1 and 8ANC131 and 8ANC134 from 
donor RU8 (Scheid et al., 2011). These 8 new structures (Figure 1, Table S2) from 7 distinct 
B cell lineages nearly double the number of lineages with structurally defined CD4bs 
antibody-gp120 complex structures (Table S3).
Structures of HIV-1 gp120 with antibodies from VH1-2 germline (VRC18 and VRC27) or 
from VH1-46 germline (1B2530, 8ANC131, and 8ANC134) revealed antibody interfaces 
dominated by the heavy chain second complementarity determining region (CDR H2) 
(Figure 2A). This “type” or mode of recognition for both VH1-2-and VH1-46-derived 
antibodies was very similar, although the binding angles of VH1-46-derived antibodies 
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relative to that of CD4 for 8ANC131 and 8ANC134 were on the outskirts of the strict 
confines of the VH1-2-derived antibodies (Figure 2B). By contrast, structures of antibodies 
from germlines other than VH1-2 or VH1-46 (VRC13, VRC16 and HJ16) revealed antibody 
interfaces dominated by CDR H3, which in each case contributed ~75% of the heavy chain 
interface (Figure 2A, Table S4). Overall, structural analysis revealed broadly neutralizing 
CD4bs antibodies to fall into two distinct types: CDR H3-dominated or VH-gene-restricted, 
and also provided characteristic features for each type of antibody recognition (Table S3).
Conserved geometry of CD4bs recognition
Despite type-specific features, gp120-binding orientations of the eight newly defined 
antibodies were similar to each other and to previously determined structures from eight 
donors (Georgiev et al., 2013; Liao et al., 2013; Wu et al., 2011; Zhou et al., 2010; Zhou et 
al., 2013) (Figure 2C). For the 15 unique broadly neutralizing CD4bs lineages, the heavy 
chain comprised the major interactive component (77±10% of the interface). For all 15, the 
light chain was oriented towards the viral membrane (Figure 2D, Figure S2). Antibodies 
targeting the CD4bs were constrained geometrically both in latitudinal accessibility, which 
defines freedom between viral and host cell membranes, and in longitudinal accessibility, 
which defines freedom within the plane of the membrane (relative to the viral spike, the 
latitudinal axis is perpendicular to the trimer axis, and the longitudinal axis is parallel to this 
axis).
While the VH-gene-restricted antibodies clustered with similar latitudinal angles, the four 
antibodies of the CDR H3-dominated type each showed latitudes, which were similar to that 
of CD4 (Figure 2C, left and upper right panels). The constraint in longitude was also 
pronounced (Figure 2C, middle and lower right panels), with most longitudes within 20°. 
Overall, the restriction in binding orientation appeared to be substantially greater than 
observed with antibodies against model antigens such as hen-egg white lysozyme (Braden et 
al., 1994; Desmyter et al., 1996; Padlan et al., 1989) or against other supersites of HIV-1 
vulnerability, such as the membrane-proximal external region on gp41, where antibodies 
2F5, 4E10 and 10E8 have divergent binding orientations (Cardoso et al., 2005; Huang et al., 
2012; Ofek et al., 2004), or the glycan-V3 supersite on gp120, where longitudinal approach 
angles ranged from 15 to 95 degrees among four representative antibodies (PGT122, 
PGT128, PGT135 and 2G12) (Calarese et al., 2003; Julien et al., 2013; Kong et al., 2013; 
Pejchal et al., 2011)(Figure S3).
To gain an overall understanding of the relationship between breadth of neutralization and 
binding orientation, we compared the orientation of CD4bs antibodies relative to the most 
effective CD4bs antibodies thus far developed, modified somatic variants of the VRC01- 
lineage such as antibody 45–46m2 or antibody VRC07-523 (Diskin et al., 2013; Diskin et 
al., 2011; Rudicell et al., 2014) (PDB 4JKP and 4OLW). For this analysis, we added three 
CDR H3-dominated recognizers – b12, b13, and F105 – to the current panel of 16 antibodies 
(Chen et al., 2009; Zhou et al., 2007). Strong correlation between antibody orientation and 
neutralization breadth was observed (p<0.0001, R2=0.64), with the VH1-2-derived 
antibodies which were the most similar in angular orientation to antibodies 45–46m2 and 
VRC07-523 also showing the highest breadth, and these were followed by VH1-46 
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antibodies and CDR H3-dominated recognizers (Figure 3, upper panel). Separate 
correlations of CDR H3- dominated and VH-gene-restricted CD4bs relative to the most 
effective antibody of each type also showed strong correlation (Figure 3, middle and lower 
panel). Altogether, effective CD4bs antibodies shared highly similar orientations, both in 
terms of overall antibody-angle of approach and in terms of heavy-light chain orientation 
relative to the spike (Figure 2 and 3). However, the two different types of antibodies –CDR 
H3-dominated and VH-gene-restricted– correlated better with breadth when treated as 
separate groups, with CD4bs antibodies clustering around two optimal structural modes of 
recognition, which were embodied by the most effective antibodies of each type (Figure 2 
and 3).
B cell ontogenies
In addition to type, which reflects structural mode of recognition, CD4bs antibodies can be 
delineated by class, which further categorizes antibodies by their B cell ontogeny (Kwong 
and Mascola, 2012; West et al., 2014). B cell ontogeny accounts for genetic similarities in 
developmental pathways and also includes maturation processes such as affinity for antigens 
that initiate B cell maturation and degree of affinity maturation required for neutralization 
breadth. Thus a single type of recognition may be achieved by different B cell ontogenies, 
resulting in different classes of antibodies (Table S3). To define the class of each of the 
CD4bs antibodies, we studied their ontogenies.
The ontogenies of VH1-2-derived CD4bs antibodies have been defined previously. As a 
group they are unified by (i) very weak to undetectable binding to gp120 of germline Vgene 
revertants of heavy and light chain in which the CDR H3 or L3 are mature (gHgL) (Jardine 
et al., 2013; Klein et al., 2013; McGuire et al., 2013; Mouquet et al., 2010; Scheid et al., 
2011; Zhou et al., 2010), (ii) similarities in heavy chain evolution (Wu et al., 2011), and (iii) 
a specific light chain sequence signature (West et al., 2012; Zhou et al., 2013). These 
characteristics define the VRC01 class of neutralizing antibodies, named for the first 
member of this class, VRC01 (Wu et al., 2010), from donor 45 (Wu et al., 2015). Among the 
new antibodies described here, VRC18 and VRC27 are members of the VRC01 class.
When we analyzed the binding of gHgL revertants of the VH1-46-derived antibodies, 
8ANC131 and 1B2530, to a panel of full-length gp120s, no detectable binding was 
observed, (Figure 4A), similar to the behavior observed for VH1-2-derived VRC01 class 
members (Scheid et al., 2011; Zhou et al., 2010). Cross-donor phylogenetic analysis (Wu et 
al., 2011) indicated that the VH1-46 derived antibodies from donor RU1 and RU8 evolved 
with sufficient similarity to allow the identification of 8ANC131 sequences with 1B2530 
sequence similarity and vice-versa (Figure 4B, Table S5). We did not observe a specific 
heavy or light chain signature. Moreover, when we analyzed immunogens capable of 
binding the gHgL of VH1-2-derived antibodies (McGuire et al., 2013), we found that the 
mature forms of antibodies 1B2530 and 8ANC131 bound well to these immunogens, but the 
gHgL of VH1-46-derived antibodies were unable to bind (Figure S4). Thus, while the 
VH1-46-derived antibodies were similar to those from the VRC01 class, the preponderance 
of ontological features indicated that VH1-46-derived antibodies form a separate class, 
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which we named the 8ANC131 class, after the most effective member of this class (Scheid 
et al., 2011).
For the CDR H3-dominated antibodies, only the ontogeny of the CH103 antibody has been 
analyzed in detail previously (Liao et al., 2013). None of the four CDR H3-dominated 
antibodies analyzed here utilized the same origin genes (VH, D, JH, VL/K, and JL/K), except 
CH103 and VRC13, which shared the same Jλ gene; however, because the light chain J-
region did not contribute substantially to recognition with either CH103 or VRC13, the Jλ-
usage was likely not critical to the ontogeny of these antibodies. We tested the recognition 
of gHgL versions of the four CDR H3-dominated antibodies: the gHgL of VRC13 and of 
VRC16 showed weak and moderate binding to several gp120s, while gHgL of CH103 and 
HJ16 showed no detectable binding (Figure 4A). In terms of heavy chain evolution, donor 
samples for B cell sequencing were available from donors 44 and C38, the sources of 
antibodies VRC13 and VRC16, respectively. Cross-donor analysis with heavy chain 
sequences showed no similarities in evolution between VRC13 and VRC16, or between 
these antibodies and any of the sequences from VH-gene-restricted donors (Figure 4B). 
Finally, we could not identify any sequence signatures in the paratopes of the CDR H3-
dominated antibodies. In light of these data on gene origin, gHgL recognition, heavy chain 
evolution, and sequence signature, we conclude that antibodies CH103, HJ16, VRC13, and 
VRC16 each have different B cell ontogenies and therefore represent separate antibody 
classes (Figure 4C and Table S3).
Epitope characteristics of CD4bs antibodies
To define the HIV-1-Env surface recognized by highly effective antibodies from 14 donors, 
we analyzed their epitopes. Recognized surfaces overlapped considerably, although 
substantial variation was observed with antibodies encoding CDR H3-dominated 
recognition. For example, HJ16 recognized an epitope that extended towards the viral 
membrane, and shared less than 50% overlap in recognized Env surface with VRC13. For 
the VH-gene-restricted antibodies, epitope surfaces revealed a characteristic discontinuity 
near the center of the epitope, a feature shared with CD4 (Figure 5A, B). This discontinuity 
was not observed for antibodies with CDR H3-dominated recognition, where the penetrating 
CDR H3 loops formed contiguous complementary molecular surfaces. To determine 
whether these differences in recognition could be detected functionally, we analyzed the 
neutralization fingerprints (Georgiev et al., 2013) for all 16 CD4bs antibodies on a panel of 
178 genetically diverse viruses (Figure 5C). While the neutralization profile of CD4bs 
antibodies segregated from antibodies targeting other Env sites, within the CD4bs cluster the 
most divergent were the VH1-46-derived and CDR H3-dominated antibodies, with 1B2530 
and HJ16 falling outside of the main CD4bs cluster. The remaining members of the CD4bs 
classes were interleaved. To provide a per-residue understanding of the CD4 supersite, we 
combined recognized epitope with neutralization potency to construct a residue-level picture 
of the CD4 supersite (Figure 5D, Figure S5). Overall, despite differences in structural mode 
of recognition and class, all of the CD4bs antibodies displayed general similarities in terms 
of recognized epitope and profile of viruses neutralized.
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Paratope characteristics of CD4bs antibodies
To understand how these antibodies recognize the CD4 supersite, we analyzed their 
paratopes. First, we structurally aligned gp120 components from co-crystal structures and 
analyzed known hot spots of CD4 interaction (Ryu et al., 1990; Wang et al., 1990) (Figure 
6) (for clarity, from this point forwards, residues are displayed with a subscript defining the 
molecule). Within domain 1 of CD4, Phe43CD4 makes contacts with the “Phe43 pocket” on 
gp120 and forms hydrophobic interactions with Glu370gp120, Ile371gp120, and Trp427gp120 
and backbone contacts with residues 425gp120 and 473gp120 (Figure 6A, Table S6). 
Interestingly, a similar hydrophobic interaction was observed in some of the VH1-2-derived 
VRC01-class antibodies, including Trp54VRC-PG20, Phe5412A21 and Phe54VRC27. Despite 
this interaction being highly favorable (Diskin et al., 2011; Rudicell et al., 2014), it was not 
preserved in other members of the VRC01 class. For example, with VRC01, residue 
54VRC01 is a glycine, and no hydrophobic residue substitutes for this interaction (Figure 
6A). For the VH1-46-derived antibodies, no similar residue is found in 8ANC131, but for 
antibody 1B2530, Arg541B2530 engages the gp120 Phe43 pocket in a manner similar to 
VH1-2 antibody VRC23. Meanwhile, with the CDR H3-dominated antibodies, in VRC16 
the phenyl ring of Tyr100EVRC16 is oriented almost identically to that of Phe43CD4, whereas 
in CH103, HJ16, and VRC13, no similar interactions are observed; indeed HJ16 does not 
even interact with the Phe43 pocket (Figure S6). Thus the specific chemical interactions at 
the Phe43 pocket of gp120 appeared to be highly variable.
In terms of the other highly favorable interaction within domain 1 of CD4, Arg59CD4 forms 
electrostatic interactions with Asp368gp120 (Figure 6B). With all of the VH-gene-restricted 
type antibodies, both from VH1-2 and VH1-46 origins, Arg71heavy chain makes similar 
interactions. Notably, the combination of a CDR H2-dominated interface along with use of 
Arg71heavy chain may explain the restricted VH-gene usage of this antibody type. Many 
common VH genes encode Arg71heavy chain, but this residue is often buried between CDR 
H2 and CDR H1 (North et al., 2011). VH1-2 and VH1-46 seem to possess CDR H2 
sequence features (such as Pro52Aheavy chain) that lead to a CDR H2 conformation that is 
compatible with gp120-binding and which exposes Arg71heavy chain (see Germline gene 
usage of the VH-gene restricted antibodies in Supplemental Information). In the CDR H3-
dominated antibodies, both CH103 and VRC13 use Arg residues (Arg97CH103 and 
Arg96VRC13) to mimic the interactions of Arg59CD4, but antibody HJ16 has no equivalent 
interactions, and antibody VRC16 uses a His side chain to approximate this interaction 
(Figure 6B). Thus the specific chemical interactions with Asp368gp120 appeared to be 
mostly, though not entirely, conserved.
To provide an overall understanding of the recognition surface, we analyzed paratope 
chemistry utilized in recognizing the CD4 supersite (Figure 7, Table S7). We observed 
substantial inter-class differences, with CDR H3-dominated antibodies displaying especially 
varied binding surfaces and interactive chemistry. We also examined intra-class differences 
between different donors with antibodies derived from common VH genes (Figure 7B). 
Among members of the VRC01 class (Figure 7B, left panels), paratope chemistry and atom 
type (Petrey and Honig, 2000) were similar, despite the paratope being altered by substantial 
somatic hypermutation. Notably this hypermutation occurred in similar regions of the 
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paratope, likely reflecting similarities in ontogeny and in requirements to achieve optimal 
recognition. Substantial diversity, however, was observed among antibodies of the 
8ANC131 class from different donors (Figure 7B, right panels).
Thus highly effective CD4bs antibodies, even those of the same B cell ontogeny, can 
develop distinct paratope chemistry. These differences in paratope chemistry indicate that 
the immune system can find diverse solutions to the recognition of the same target epitope.
DISCUSSION
While antibodies of the human immune system can recognize epitopes in diverse ways, 
repeated observations in 14 donors of similar geometries of recognition and similar B cell 
ontogenies suggest the repertoire for broad neutralization to be relatively limited. One 
potential explanation for this limitation is that HIV-1 Env is so well protected from antibody 
recognition that the humoral immune system can develop effective recognition – even 
against the more prevalently recognized supersites of Env vulnerability – through only a few 
pathways.
It may be important to identify critical factors that constrain the development of effective 
recognition, and one way to do this is to analyze the recognition of multiple antibodies that 
target the same supersite at the population level. Elements of diversity between these 
antibodies would indicate factors that allow the immune system to develop multiple 
solutions; elements of similarity would indicate dominant constraining factors. In the case of 
the CD4 supersite, we observed the overall geometry of antibody recognition to be highly 
similar (Figure 7A); this suggested a dominant constraining factor for the elicitation of 
CD4bs antibodies to be paratope accessibility at the recessed CD4 supersite on functional 
viral spikes (Lyumkis et al., 2013; Pancera et al., 2014).
The 14 donors analyzed here define our current understanding of the human antibody 
repertoire that can effectively recognize the CD4 supersite on HIV-1. While surrounded by 
glycan, the surface that binds CD4 is itself free of glycan (Kwong et al., 1998): indeed it is 
the only epitope cluster on the HIV-1-Env spike that is both glycan-free and not 
membraneproximal (Pancera et al., 2014). The VH-gene-restricted classes that successfully 
target this site each appear in multiple donors and share evolutionary similarities, suggesting 
developmental pathways accessible to the general population. By contrast, the CDR H3-
dominated classes each appear in a single donor and show no detectable evolutionary 
similarity or sequence signature, suggesting origins that are stochastic and therefore not 
shared between different individuals. Because the germline-reverted (gHgL) versions of the 
VH-gene-restricted and CDR H3-dominated antibodies showed different binding behaviors 
to gp120, we assessed their B cell activation properties to provide insight into early 
development. Calcium flux experiments indicated that B cell triggering could occur with 
gHgL versions of VRC13, but not VRC01 (Figure S4), demonstrating differences in 
ontogeny whereby germline versions of some CDR H3-dominated antibodies could trigger 
B cell activation more efficiently than germline-reverted versions of antibodies from VH-
gene-restricted classes. This was supported by the binding of the germline-reverted version 
of the CDR H3-dominated VRC13 and VRC16 (Figure 2), by the autologous-virus specific 
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binding of the unmutated common ancestor of the CDR H3-dominated CH103 (Liao et al., 
2013), and by the lack of binding for germline-reverted versions of VH-gene-restricted 
antibodies (Figure 4, Figure S4) (Jardine et al., 2013; McGuire et al., 2013; Zhou et al., 
2010). Finally the inability of germline-reverted VH1-46 antibodies to bind immunogens, 
which had been developed to recognize germline-reverted VH1-2 antibodies, indicated that 
different classes of VH-gene-restricted antibodies may require different immunogens. 
Together, the results suggest that distinct immunogens may be required to stimulate the 
development of the different types and classes of broadly neutralizing antibodies that 
recognize the CD4 supersite.
Overall, the CD4bs antibody analysis described here, the first comprehensive analysis of 
antibody recognition for a supersite of HIV-1 vulnerability, provides a framework linking 
structural mode of antibody recognition (type) with B cell ontogeny (class) and paratope 
chemistry in 14 donors (Table S3). Serum from these donors displayed a range of potencies, 
though with breadths generally in the upper range (Figure S7). This population-level 
analysis provides insight into constraining factors (e.g. from similarities in elicited 
antibodies) as well as the ease by which the immune system can replicate a particular 
lineage pathway (e.g. from similarities in ontogeny). The results indicate that the repertoire 
for effective recognition of the CD4 supersite consists of antibodies with diverse paratopes 
that cluster around two solutions: one achieved by VH-gene-restricted ontogenies and the 
other achieved by CDR H3- dominated ontogenies. The VH-gene-restricted solution, 
embodied by antibodies 45–46m2 and VRC07-523 (Diskin et al., 2013; Rudicell et al., 
2014), uses the CDR H2 region to mimic the C’’ recognition of CD4 (Kwong et al., 1998), 
though with a different latitudinal orientation to accommodate the light chain (Zhou et al., 
2010). The CDR H3-dominated solution, embodied by antibody VRC13 isolated here, uses 
the CDR H3 region to recognize the CD4 supersite, with the same latitudinal angle as CD4. 
It will be interesting to see if additional broadly neutralizing CD4bs antibodies will continue 
to cluster around these two solutions and whether other highly effective solutions to the 
problem of antibody recognition of the CD4 supersite can be found.
EXPERIMENTAL PROCEDURES
Human Specimens
Donors 44, C38 and Z258 participated in NIAID protocols (Doria-Rose et al., 2009) at the 
National Institutes of Health, Bethesda, MD, USA. HIV infection was documented by 
HIV-1/2 immunoassay. The donors were chronically infected and had not initiated 
antiretroviral treatment at the time of sample collection. All human samples were collected 
with informed consent under clinical protocols approved by the appropriate institutional 
review board (IRB).
Isolation and Expression of Antibody 44-VRC13.01, C38-VRC16.01, C38-VRC18.02 and 
Z258-VRC27.01
Antigen-specific memory B cells from donors 44, C38 and Z258 were isolated with 
Avitagged RSC3 and ΔRSC3 and single-cell sorted on a FACS Aria II as described 
previously (Wu et al., 2010). (Extended Experimental Procedures)
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Production and Purification of HIV-1 Env Protein and Antibodies
HIV-1 gp120 proteins were produced in GNTI −/− cells and purified as described previously 
(Zhou et al., 2010). Human antibodies were expressed in HEK293F cells and purified by 
Protein A affinity columns. Antigen-binding fragments (Fab) of antibodies were prepared by 
overnight Lys-C digestion at 37°C with a IgG:Lys-C ratio of 4000:1 (w/w), and sequential 
purification over Protein A and size exclusion columns.
Neutralization Assays
Single round of replication Env-pseudoviruses were prepared, titered and used to infect 
TZM-bl target cells as described previously (Montefiori, 2009) (Extended Experimental 
Procedures and Table S1).
Formation of Protein Complexes, Crystallization, and Data Collection
The gp120-antibody complexes were formed by mixing deglycosylated HIV-1 gp120 with 
antibody Fab in a 1:1.2 molar ratio. The complexes were purified by size exclusion 
chromatography. Fractions with gp120-antibody complexes were concentrated to ~10 mg/ml 
for crystallization experiments. Crystallization conditions for all gp120-Fab complexes were 
obtained robotically and manually optimized in hanging drops (Extended Experimental 
Procedures).
Structure Determination and Refinement
All structure was solved by molecular replacement with Phaser (McCoy et al., 2007). 
Iterative model building and refinement procedures were carried out using Coot (Emsley 
and Cowtan, 2004) and Phenix (Adams et al., 2010) (Extended Experimental Procedures and 
Table S2).
Bioinformatics Analysis of Antibody Neutralization and 454 Sequencing Data
The neutralization fingerprint of antibodies were analyzed with procedures described 
previously (Georgiev et al., 2013). High throughput B cell sequencing of donor samples, 
bioinformatics processing of sequencing data and cross-donor phylogenetic analysis of 
antibody sequences were carried out with similar procedures as described (Wu et al., 2011; 
Zhu et al., 2012) (Extended Experimental Procedures and Table S5)
Structural Analysis
All antibody complexes were aligned over the outer domain of HIV-1 gp120 to gain a 
common reference frame for further comparison of the modes of recognition to the CD4- 
binding site. The BG505.664 SOSIP crystal structure (PDB ID: 4TVP) was used to analyze 
antibody recognition on the HIV-1 viral spike (Pancera et al., 2014). (Extended 
Experimental Procedures).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Population-level analysis revealed only two types of effective CD4bs antibodies.
• Each type, CDR H3-dominated or VH-gene-restricted, had distinct ontogenies.
• Both types could neutralize effectively, each with an optimal angle of approach.
• Despite geometric similarities, paratope chemistries were extremely diverse.
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Figure 1. Crystal Structures of Eight CD4bs Antibodies in Complex with HIV-1 gp120 Show 
Similar Heavy and Light Chain Orientations
Complex structures are shown from a common alignment with gp120 (gray surface 
representation), with the light chain shown in blue and the heavy chains shown in red, green, 
and brown for CDR H3-dominated recognizers, VH1-2-derived heavy chains, and VH1-46-
derived heavy chains, respectively. See also Figure S1, Table S1 and S2.
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Figure 2. Broadly Neutralizing CD4bs Antibodies Fall into Two Types: CDR H3- Dominated 
and VH-Gene-Restricted (VH1-2 or VH1-46)
(A) Percent of surface area buried in the gp120 interface for each CDR of heavy chain (left) 
and light chain (right). (B) Orientation of heavy-chain component of CD4bs antibody on 
gp120 relative to CD4. Structures determined here are shown as solid squares. Notably, 
newly determined structures - 8ANC131, VRC13, VRC16, and HJ16 - have orientations that 
differ from the previously published VRC01-class and CH103 antibodies. (C) Angles of 
approach for CD4bs antibodies on the trimer spike in its pre-fusion near-native 
conformation. Left, the HIV-1 Env trimer is shown as a gray surface with N-linked glycans 
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in teal stick representation. The CD4-binding site on the outer domain of gp120 is 
represented as a yellow surface; the binding orientation of CD4 (domains 1 and 2) is shown 
with a yellow line; the binding orientations of CD4bs antibodies are shown with a red line 
for CDR H3-dominated, green for VH1-2-gene-restricted, and brown for VH1-46-gene-
restricted. Right, histogram of explicit angles of approach are provided in the trimer 
coordinate system shown at left in which a latitudinal angle of 0 coincides with the trimer 3-
fold axis. (D) Binding orientation for CDR H3-dominated and VH-gene-restricted CD4bs 
antibodies. The light chains of antibodies are colored in slate blue and the heavy chains are 
colored red for CDR H3-dominated antibodies, dark green for VH1-2-gene restricted 
antibodies, and brown for VH1-46-restricted antibodies. See also Figure S2 and S3, Table 
S3 and S4.
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Figure 3. Neutralization Breadth of CD4bs Antibodies Correlates with Angular Difference from 
the Most Effective Antibodies
Correlation between antibody breadth and the angular difference of the heavy chain relative 
to the most effective antibodies. Upper panel, all CD4bs antibodies relative to the most 
effective antibody, VRC07-523; Middle panel, CDR H3-dominated antibodies relative to the 
most effective CDR H3-dominated antibody, VRC13; Lower panel, VH-gene-restricted 
antibodies relative to the most effective VH-gene-restricted antibody, VRC07-523. For 
clarity, antibodies are only labeled in the middle and lower panels. To determine a common 
reference frame for calculations of angular difference, antibody-gp120 structures were first 
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aligned to a common reference frame based on core gp120; to determine angular difference 
relative to the most effective antibody, a second superposition was performed to align each 
antibody to the most effective antibody referent; rotation angles determined from this second 
superposition are shown.
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Figure 4. Characteristics of B Cell Ontogenies for Effective CD4bs Antibodies
(A) Affinities for germline reverted (gHgL) and mature antibodies to six diverse gp120s. 
Clade of each isolate is shown in parentheses after the strain name. (B) Similarities in heavy 
chain maturation. Numbers in the table correspond to the number of heavy chain sequences 
retrieved from heavy chain transcripts determined by NGS of B cells from each donor; 
retrieval was accomplished by cross-donor phylogenetic analysis with the template antibody 
from the first column. Gray highlighted areas correspond to matching lineages and classes. 
The table diagonal represents matching antibodies and donors; when antibodies are found 
off the diagonal, this indicates similarity in heavy chain maturation. (C) Class characteristics 
of effective CD4bs antibodies. See also Figure S4 and Table S5.
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Figure 5. The CD4 Supersite
(A) Antibodies from 14 donors define an immunological supersite of HIV-1 vulnerability. A 
composite of the breadth-coded epitope surfaces shown in (B) are mapped to the gp120 
surface. The yellow outline defines the outer-domain contact of the CD4 receptor. (B) 
Epitopes of CD4bs antibodies colored by breadth. (C) Dendrogram constructed from 
similarities in neutralization fingerprint based on serologic analysis with a 178 virus panel; 
insert shows the HIV-1 viral spike, with membrane at top, with major epitopes labeled; 
epitope colors correspond to antibody colors in the dendrogram. (D) Potency of CD4-
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binding site antibodies mapped to the supersite. The worm representation of HIV-1 gp120 is 
colored by averaged antibody potency with thickness representing average buried binding 
surface area of corresponding residues; notably, in addition to the outer domain contact on 
gp120 for CD4, neighboring regions in the inner domain and on strands β20/21 contribute to 
the supersite. See also Figure S5.
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Figure 6. Paratopes of Effective CD4bs Antibodies Are Extremely Diverse
Recognition hotspots of CD4bs antibodies and CD4 are shown with antibodies labeled by 
class (top line) and representative member (bottom line). (A) CD4bs recognition of Phe43 
cavity. Antibody or CD4 are shown in ribbon representation, with the side chain closest to 
the Phe43 cavity shown in stick representation; gp120 is shown as a gray surface. (B) 
CD4bs recognition of Asp368 on gp120. Coloring is the same as in (A), but gp120 is shown 
in ribbon representation, with the Asp368 side chain in stick representation. See also Figure 
S6 and Table S6.
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Figure 7. Chemistry of CD4 Supersite Recognition by Effective Neutralizing Antibodies
(A) Chemistry of recognition surfaces is shown for each of the CD4bs antibody classes and 
CD4. Antibody 8ANC131 is shown for 8ANC131 class; VRC01 is shown for the VRC01 
class. Insets show these representative members of each antibody class bound to the CD4 
supersite on the HIV-1 Env trimer (gray surface, with N-linked glycans shown in teal stick 
representation). (B) Intra-class comparison of paratope atom type (top row, colored as in key 
for (A)) and somatic hypermutation (bottom row, with colors defined in key for (B)). See 
also Figure S7 and Table S7.
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